Skip to main navigation Skip to search Skip to main content

A novel human PTH analog [Cys25]hPTH(1-34) restores bone mass in ovariectomized mice

  • Chu Hyun Bae
  • , Myeongmo Kang
  • , Clara Yongjoo Park
  • , Bo Mi Park
  • , Dongdong Zhang
  • , Hee Jin Nam
  • , Yu Mi Yang
  • , Dong Min Shin
  • , Je Yong Choi
  • , Sung Kil Lim
  • Yonsei University
  • Kyungpook National University

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Context: Recently, an arginine-to-cysteine homozygous mutation at position 25 in mature PTH was reported in a Korean patient with hypoparathyroidism. Objective: To clarify whether the high bone mass phenotype observed in this patient was related to the hypoparathyroidism itself or to chronic elevation of mutant PTH. Methods: A series of in vitro and in vivo experiments were performed in MC3T3E1, ROS 17/2.8, and SAOS2 cells treated with human (h)PTH(1-34), Cys25hPTH(1-34), Ala1Cys25hPTH(1-34), and Bpa1Cys25hPTH(1-34). The peptides were then sc delivered to ovariectomized mice as daily single injections. Results: Compared with hPTH(1-34) and Ala1Cys25hPTH(1-34), treatment with Cys25hPTH(1-34) or Bpa1Cys25hPTH(1-34) resulted in decreases in the cAMP response and promoter-cAMP-response element luciferase reporter activity. Although the cAMP response was sustained with hPTH(1-34) in MC3T3E1 cells, such response was not observed with the other mutated peptides. Meanwhile, all PTH analogues exhibited ERK phosphorylation and cytoplasmic Ca signals comparable with hPTH(1-34). On microcomputed tomography analyses, trabecular and cortical bone parameters improved after 6 weeks of respective treatments as follows: hPTH(1-34) (80 μg/kg)-Ala1Cys25hPTH(1-34)(80 μg/kg)-Cys25hPTH(1-34)(80 μg/kg)-Bpa1Cys25hPTH(1-34)(80 μg/kg)-hPTH(1-34) (40 μg/kg). The increment of RANKL to OPG mRNA ratio in the MC3T3E1 cells after 6 hours of treatment of Cys25hPTH(1-34), AL1Cys25hPTH(1-34), and Bpa1Cys25hPTH(1-34) was less than that was obtained after hPTH(1-34) treatment. On bone histomorphometric analysis, AL1Cys25hPTH(1-34) increased the bone formation rate in both trabecular and periosteal bones compared with the control group. Conclusion: The high bone mass phenotype observed in this patient with hypoparathyrodism caused by a Cys mutation at the 25th residue of hPTH(1-84) may have arisen from both direct and indirect effects exerted by the mutant PTH itself on bone.

Original languageEnglish
Pages (from-to)3700-3708
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number10
DOIs
StatePublished - Oct 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'A novel human PTH analog [Cys25]hPTH(1-34) restores bone mass in ovariectomized mice'. Together they form a unique fingerprint.

Cite this